Mustang Bio Inc (NASDAQ:MBIO) shares reached a new 52-week high on Thursday . The stock traded as high as $10.20 and last traded at $6.15, with a volume of 449852 shares. The stock had previously closed at $2.66.
MBIO has been the subject of several research reports. Zacks Investment Research upgraded Mustang Bio from a “sell” rating to a “hold” rating in a research note on Thursday, January 17th. Oppenheimer set a $18.00 price target on Mustang Bio and gave the stock a “buy” rating in a research note on Tuesday, March 19th. Finally, ValuEngine upgraded Mustang Bio from a “hold” rating to a “buy” rating in a research note on Monday, April 1st.
The company has a market capitalization of $78.73 million, a P/E ratio of -4.95 and a beta of 2.37.
Hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. raised its holdings in shares of Mustang Bio by 0.7% in the 4th quarter. BlackRock Inc. now owns 825,043 shares of the company’s stock valued at $2,426,000 after acquiring an additional 5,566 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Mustang Bio by 4.1% in the 4th quarter. Geode Capital Management LLC now owns 170,217 shares of the company’s stock valued at $500,000 after acquiring an additional 6,741 shares in the last quarter. National Asset Management Inc. raised its holdings in shares of Mustang Bio by 13.4% in the 4th quarter. National Asset Management Inc. now owns 82,325 shares of the company’s stock valued at $243,000 after acquiring an additional 9,700 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Mustang Bio by 27.8% in the 4th quarter. Bank of New York Mellon Corp now owns 55,668 shares of the company’s stock valued at $163,000 after acquiring an additional 12,111 shares in the last quarter. Finally, Fenimore Asset Management Inc. purchased a new stake in shares of Mustang Bio in the 4th quarter valued at about $112,000. Institutional investors and hedge funds own 8.71% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Mustang Bio (MBIO) Reaches New 52-Week High at $10.20” was reported by Markets Daily and is the property of of Markets Daily. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.themarketsdaily.com/2019/04/18/mustang-bio-mbio-reaches-new-52-week-high-at-10-20.html.
Mustang Bio Company Profile (NASDAQ:MBIO)
Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
Featured Story: How Do You Calculate Return on Investment (ROI)?
Receive News & Ratings for Mustang Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mustang Bio and related companies with MarketBeat.com's FREE daily email newsletter.